Skip to content

ZIKA DIAGNOSTICS, INC

company.status.inactive

CIK 1510333fmd_0HWJH5TPTPREB82RXX4YQS93R6Services · Services-Allied To Motion Picture ProductionTemplate: Standard

Coverage: May 15, 2009 to Jul 31, 2016, 23 periods

Latest annual · FY2013

Millions
Total revenues
0
Operating income
(0)
Net income
(0)

Latest quarter · Q2 FY2016

Millions
Operating income
(0)
Net income
(0)
Open Financials

Key stats

Open Analysis

Compound annual growth

Net income, 5 yearsFY2011 to FY2016
n/m

ZIKA DIAGNOSTICS, INC financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2016FY2015ChangeSource
Operating income-$43,906-$33,26910-K 2016-07-21 · proof
Net income-$50,735-$37,90610-K 2016-07-21 · proof
Cash from operating activities-$56,843-$17,66410-K 2016-07-21 · proof
What was ZIKA DIAGNOSTICS, INC's operating income in fiscal 2016?
ZIKA DIAGNOSTICS, INC reported operating income of -$43,906 for fiscal 2016 (the year ended Apr 30, 2016), against -$33,269 the year before. Source: the 10-K filed with the SEC on Jul 21, 2016. SEC
What was ZIKA DIAGNOSTICS, INC's net income in fiscal 2016?
ZIKA DIAGNOSTICS, INC reported net income of -$50,735 for fiscal 2016 (the year ended Apr 30, 2016), against -$37,906 the year before. Source: the 10-K filed with the SEC on Jul 21, 2016. SEC
What was ZIKA DIAGNOSTICS, INC's cash from operating activities in fiscal 2016?
ZIKA DIAGNOSTICS, INC reported cash from operating activities of -$56,843 for fiscal 2016 (the year ended Apr 30, 2016), against -$17,664 the year before. Source: the 10-K filed with the SEC on Jul 21, 2016. SEC

Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1510333&period_type=annual&limit=5"

Information only, not investment advice.